S

Shanghai Henlius Biotech Inc
HKEX:2696

Watchlist Manager
Shanghai Henlius Biotech Inc
HKEX:2696
Watchlist
Price: 20.25 HKD -0.25% Market Closed
Market Cap: 11B HKD
Have any thoughts about
Shanghai Henlius Biotech Inc?
Write Note

Relative Value

The Relative Value of one Shanghai Henlius Biotech Inc stock under the Base Case scenario is 27.75 HKD. Compared to the current market price of 20.25 HKD, Shanghai Henlius Biotech Inc is Undervalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
27.75 HKD
Undervaluation 27%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
76
vs Industry
79
Median 3Y
2
Median 5Y
5.2
Industry
7.7
Forward
1.8
vs History
11
vs Industry
8
Median 3Y
-9
Median 5Y
-12.1
Industry
22.7
Forward
17.1
vs History
17
vs Industry
12
Median 3Y
6.5
Median 5Y
-28
Industry
21.6
vs History
vs Industry
3
Median 3Y
11.3
Median 5Y
-17.4
Industry
25.2
vs History
61
vs Industry
17
Median 3Y
3.8
Median 5Y
4.3
Industry
2.5
vs History
76
vs Industry
68
Median 3Y
2.1
Median 5Y
5.4
Industry
7.7
Forward
1.9
vs History
76
vs Industry
65
Median 3Y
2.9
Median 5Y
7.9
Industry
9
vs History
19
vs Industry
9
Median 3Y
-10.8
Median 5Y
-15.9
Industry
4.2
Forward
12.4
vs History
14
vs Industry
7
Median 3Y
-9.1
Median 5Y
-11.7
Industry
4.1
Forward
15.3
vs History
17
vs Industry
11
Median 3Y
6.8
Median 5Y
-26.8
Industry
5.7
vs History
17
vs Industry
0
Median 3Y
-4.7
Median 5Y
-11.1
Industry
3.6
vs History
60
vs Industry
53
Median 3Y
1
Median 5Y
1.5
Industry
4.6

Multiples Across Competitors

Competitors Multiples
Shanghai Henlius Biotech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Shanghai Henlius Biotech Inc
HKEX:2696
11B HKD 1.8 14.8 9 13
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
CN
S
Shanghai Henlius Biotech Inc
HKEX:2696
Average P/E: 176
14.8
89%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
S
Shanghai Henlius Biotech Inc
HKEX:2696
Average EV/EBITDA: 16
9
20%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
S
Shanghai Henlius Biotech Inc
HKEX:2696
Average EV/EBIT: 21.2
13
74%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top